

[x](#)

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
 - For example, a search on Aminosalicyclic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
 - A search for “Aminosalicyclic Acid Tablets” will result in anything that specifically contains “Aminosalicyclic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
 - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NAPHAZOLINE IM	<i>First</i>	8105	18-Nov-2016	1-Dec-2016	<i>USP41–NF36</i>	<i>Second</i>	Line 16 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE	PURITIES/Organic Impurities	<i>Supplement to USP39–NF34</i>						<i>Supplement to USP40–NF35</i>	<i>Analysis:</i> Change Calculate the percentage of any individual unspecified impurity to: Calculate the percentage of any other individual impurity AND Line 20 of <i>Analysis:</i> Change r_U = peak response of any individual unspecified impurity to: r_U = peak response of any other individual impurity
CIPROFLOXACIN	ADDITIONAL REQUIREMENT S/USP Reference	<i>Second Supplement to USP39–NF34</i>	8597	18-Nov-2016		1-Dec-2016	<i>USP41–NF36</i>	<i>Second Supplement to USP40–NF35</i>	Line 2 of USP Ciprofloxacin Et hylenediamine Analog RS:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
<i>Standards <11></i>									Change 7-(2-Aminoethyl amino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. $C_{15}H_{16}FN_3O_3$ 305.30 to: 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)amino]-3-quinolinecarboxylic acid hydrochloride. $C_{15}H_{16}FN_3O_3 \cdot HCl$ 341.77
CIPROFLOXACIN HYDROCHLORIDE	ADDITIONAL REQUIREMENTS	<i>Second Supplement to USP39–NF35 S/USP Reference Standards <11></i>	8600	18-Nov-2016		1-Dec-2016	<i>USP41–NF36</i>	<i>Second Supplement to USP40–NF35</i>	Line 2 of USP Ciprofloxacin Ethylenediamine Analog RS: Change 7-(2-Aminoethyl amino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
									$^{15}\text{H}_{16}\text{FN}_3\text{O}_3$ 305.30 to: 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)amino]-3-quinolinecarboxylic acid hydrochloride. $\text{C}_{15}\text{H}_{16}\text{FN}_3\text{O}_3 \cdot \text{HCl}$ 341.77
DEXTROSE	IDENTIFICATION	<i>Second Supplement to USP39–NF34 <921></i>	8612	18-Nov-2016		1-Dec-2016	<i>USP41–NF36</i>	<i>Second Supplement to USP40–NF35</i>	Line 1: Change <i>Water Determination <921></i> to: <i>Water Determination <921>, Method I</i>
OMEGA-3-ACID ETHYL ESTERS CAPSULES	ASSAY/Content of EPAee, DHAee, and Total Omega-3-Acid Ethyl Esters	<i>Second Supplement to USP39–NF34</i>	8755	18-Nov-2016		1-Dec-2016	<i>USP41–NF36</i>	<i>Second Supplement to USP40–NF35</i>	Line 21 of <i>Analysis</i> : Change C_U = nominal concentration of the total omega-3-acid ethyl esters in the <i>Sample solution</i> (g/mL)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OMEGA-3-ACID ETHYL ESTERS CAPSULES	SPECIFIC TESTS/ Concentration of Omega-3-Acid Ethyl Esters	Second Supplement to USP39–NF34	8755	18-Nov-2016	1-Dec-2016	USP41–NF36	Second Supplement to USP40–NF35		to: C_U = Capsule fill content of the <i>Sample solution</i> (g/mL) Line 21: Change C_U = nominal concentration of the total omega-3-acid ethyl esters in the <i>Sample solution</i> (g/mL) to: C_U = Capsule fill content of the <i>Sample solution</i> (g/mL)
POVIDONE	IMPURITIES/ <i>Formic Acid</i>	Second Supplement to USP39–NF34	8778	18-Nov-2016	1-Dec-2016	USP41–NF36	Second Supplement to USP40–NF35		Line 3 of <i>Sample solution</i> : Change column of about 80 mm to: column of about 8 mm
ROPINIROLE EXTENDED-RELEASE	PERFORMANCE TESTS/	Second Supplement to USP39–NF34	8814	18-Nov-2016	1-Dec-2016	USP41–NF36	Second Supplement to USP40–NF35		Line 2 of <i>Buffer 1</i> : Adjust with <i>Solution A</i> to a

Monograph Title Section		Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	<i>Dissolution <711>/Test 1</i>							pH of 4.0. to: Adjust with <i>Solution A</i> to a pH of 4.0. Dilute with water to 1 L.
PLASTIC MATERIALS OF CONSTRUCTION	TEST METHODS	<i>USP40–NF35</i>	542	18-Nov-2016	1-Dec-2016	<i>USP41–NF36</i>	<i>Second Supplement to USP40–NF35</i>	Line 1 of <i>Physicochemical Tests/Acidity or Alkalinity/BRP indicator solution</i> : Change 1.0 mg/mL of bromophenol blue, to: 1.0 mg/mL of bromothymol blue, AND Line 3 of <i>Plastic Additives/ Polyethylene, Cyclic Olefins, and Poly</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<i>propyl</i> <i>ene/Phenolic</i> <i>Anti</i> <i>oxidants/Test B:</i> Change tris(2, 4-di-<i>tert</i> -butylphenyl) phosphate; to: tris(2, 4-di-<i>tert</i> -butylphenyl) phosphite; AND Line 1 of <i>Plastic</i> <i>Additiv</i> <i>es/</i> <i>Polyethylene,</i> <i>Cyclic Olefins,</i> <i>and</i> <i>P</i> <i>oly</i> <i>propyl</i> <i>ene/Phenolic</i> <i>Anti</i> <i>oxidants/Test</i> <i>C/Mobile phase:</i> Change (55:45:5, v/v/v) to:

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							(50:45:5, v/v/v) AND Line 1 of <i>Plastic Additives/ Polyethylene, Cyclic Olefins, and Polypropylene/ Nonphenolic Anti oxidant system/ Application: Change 20 µL of Sample solution S10, reference solution (o) and the reference solutions corresponding to: 20 µL of</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DUTASTERIDE IM PUR ITIES/Organic Impurities, Procedure	USP40–NF35	3924	18-Nov-2016	1-Dec-2016	USP41–NF36	Second Supplement to USP40–NF35	<i>Sample solution S10 and the reference solutions corresponding to AND Line 2 of Plastic Additives/Plasticized Polyvinyl Chloride/USP Reference Standards <11>/USP Plastic Additive 05 RS: Change Tris(2,4-di-tert-butylphenyl) phosphate. to: Tris(2,4-di-tert-butylphenyl) phosphite. Footnote a: Change (5?,17 ?)-N-[2,5-Bis(trifluor</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	2/	Table 4							omethyl)phenyl] -3-oxo-4-azaan drost-17 carboxamide. to: (5?,1 7?)-N -[2,5-Bis(trifluor omethyl)phenyl] -3-oxo-4-azaan drostane-17-car boxamide.
ANALYTICAL DATA—INTERPEXAMPLES OF RETATION AND TREATMENT	APPENDIX C: OUTLIER TESTS FOR ANALYTICAL DATA/ <i>Hampel's Rule</i>	USP39–NF34	767	30-Sep-2016		1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Row 13 of Column 4 of Table 5. Test Results of Re-Applied <i>Hampel's Rule</i> : Change 0.14 to: 0.15
CALCIUM GLUCONATE	CHEMICAL INFORMATION	USP39–NF34	2877	30-Sep-2016		1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 5: Change [18016-24-5]. to: [66905-23-5].
CALCIUM GLUCONATE INJECTION	DEFINITION	USP39–NF34	2879	30-Sep-2016		1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 8: Change It may contain sodium hydroxide added for

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUORESCEIN ASSAY/ SODIUM <i>Procedure</i>	USP39–NF34	3960	30-Sep-2016	1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	adjustment of the pH. to: It may contain sodium hydroxide or hydrochloric acid added for adjustment of the pH. Line 3 of <i>Standard stock solution</i> : Change 1.0 mg/mL of fluorescein sodium in <i>Diluent</i> is prepared as follows. to: 1.0 mg/mL of fluorescein sodium is prepared as follows.
NORFLOXACIN SPECIFIC TESTS/ <i>Loss on Drying <731></i>	USP39–NF34	5101	30-Sep-2016	1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 1 of <i>Analysis</i> : Change Dry at 100° to constant weight.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PARICALCITOLIM INJECTION	PURITIES/ <i>Organic Impurities/Chromatographic system/Columns</i>	USP39–NF34	5279	30-Sep-2016		1-Oct-2016	USP41–NF36	First Supplement to USP40–NF35	to: Dry under vacuum at a pressure not exceeding 5 mm of mercury at 100° to constant weight. Line 1 of <i>Guard</i> : Change 4.6-mm × 7.5-mm; packing L1 to: 4.6-mm × 7.5-mm or 4.6-mm × 10-mm; packing L1
PHENYTOIN SODIUM	IDENTIFICATION N/B. <i>Identification Tests—General, Sodium <191></i>	USP39–NF34	5388	30-Sep-2016		1-Oct-2016	USP41–NF36	First Supplement to USP40–NF35	Line 2: Change tetramethylammonium hydroxide solution, to: tetramethylammonium hydroxide TS,
POTASSIUM CITRATE EXTENDED-RELEASE	OTHER COMPONENTS/ <i>Content of</i>	USP39–NF34	5465	30-Sep-2016		1-Oct-2016	USP41–NF36	First Supplement to USP40–NF35	Line 10 of <i>Analysis</i> : Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RELEASE TABLETS	Potassium								Result = $(C/C_U) \times [M_r/(3 \times A_r)] \times 100$ to: Result = $C \times 100/C_U$ AND Line 13 of <i>Analysis</i>: Change C_U = nominal concentration, based on the Assay value, of potassium citrate monohydrate in the <i>Sample solution</i> (µg/mL) M_r = molecular weight of potassium citrate monohydrate, 324.41 A_r = atomic weight of potassium, 39.10 to: C

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							$U =$ concentration of potassium citrate anhydrous ($C_6H_5K_3O_7$) in the <i>Sample solution</i> calculated from the Assay value of potassium citrate monohydrate ($C_6H_5K_3O_7 \cdot H_2O$) ($\mu g/mL$)
PROPOFOL	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	USP39–NF34 5573	30-Sep-2016	1-Oct-2016	USP41–NF36	First Supplement to USP40–NF35	Line 2 of USP Propofol Related Compound B RS: Change 2,6-Diisopropylbenzoquinone. to: 2,6-Diisopropyl-1,4-benzoquinone.
PROPOFOL INJECTABLE EMULSION	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	USP39–NF34 5575	30-Sep-2016	1-Oct-2016	USP41–NF36	First Supplement to USP40–NF35	Line 2 of USP Propofol Related Compound B RS: Change

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TRAVOPROST ADDITIONAL R OPHTHALMIC EQUIREMENT SOLUTION S/USP Reference Standards <11>	USP39–NF34	6226	30-Sep-2016	1-Oct-2016	USP41–NF36	First Supplement to USP40–NF35	2,6-Diisopropylb enzoquinone. to: 2,6-Diisopropyl -1,4-benzoquino ne. Line 2 of USP Travoprost Related Compound A RS: Change (5Z,13E)-(9S ,11R,15R)-9,11,15-Trihyd roxy-1 6-(m -trifluoromethylp henoxyl)-17,18,1 9,20-tetranor-5, 13-prostadienoi c acid. to: (5Z,13E)-(9S ,11R,15R)-9,11,15-Trihyd roxy-1 6-(m -trifluoromethylp henoxyl)-17,18,1 9,20-tetranor-5, 13-prostadienoi

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VITAMIN A ORAL LIQUID PREPARATION	ASSAY/ <i>Vitamin A</i>	USP39–NF34	6374	30-Sep-2016	1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>		c acid or (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((R,E)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl)cyclopentyl)hept-5-enoic acid. Line 7 of <i>Analysis</i> : Change Result = $(r_U/r_S) \times (C/W) \times (V/D) \times U \times (100/L)$ to: Result = $(r_U/r_S) \times (C/W) \times D \times U \times (100/L)$ AND Line 16 of the <i>Analysis</i> : Delete V = volume of the <i>Sample solution</i> (mL) Insert missing test: <i>Articles of</i>
ST. JOHN'S WORT	SPECIFIC TESTS	USP39–NF34	6817	30-Sep-2016	1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>		

<u>Monograph TitleSection</u>	<u>Source Publication</u>	<u>Page Number</u>	<u>Errata Post Date Sort ascending</u>	<u>Errata Official Date</u>	<u>Target Errata Print Publication</u>	<u>Target Online Fix Publication</u>	Description
HAZARDOUS REFERENCES DRUGS—HANDLING IN HEALTHCARE SETTINGS	<i>First Supplement to USP39–NF34</i>	7721	30-Sep-2016	1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	<i>Botanical Origin</i> <561>, <i>Methods of Analysis</i>, <i>Total Ash</i>: NMT 5.0% Line 2 of first reference: Delete http://www.acoem.org/Reproductive_Developmental_Hazard_Management.aspx. AND Line 2 of second reference: Delete http://www.asco.org/advocacy/worker-safety-when-handling-hazardous-drugs-focus-statement-oncology-societies.
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE <i>Appendix 3:</i>	<i>First Supplement to USP39–NF34</i>	7721	30-Sep-2016	1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 5 of <i>Type A1 (formerly, Type A)</i> : Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SETTINGS	<i>Types of Biological Safety Cabinets/Class II</i>								radionucleotide s to: radionuclides AND Line 5 of <i>Type A2 (formerly, Type B3)</i> : Change radionucleotide s to: radionuclides AND Line 5 of <i>Type B1</i> : Change radionucleotide s to: radionuclides AND Line 5 of <i>Type B2 (total exhaust)</i> : Change radionucleotide s to: radionuclides
DANTROLENE IDENTIFICATION SODIUM	N/D.	<i>First Supplement to</i>	8035	30-Sep-2016		1-Oct-2016	<i>USP41–NF36</i>	<i>First Supplement to</i>	Line 2 of <i>Solution A</i> :

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
		USP39–NF34						USP40–NF35	Change tetramethylammonium hydroxide solution to: tetramethylammonium hydroxide TS
OXYMETAZOLINE HYDROCHLORIDE	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	First Supplement to USP39–NF34	8116	30-Sep-2016		1-Oct-2016	USP41–NF36	First Supplement to USP40–NF35	USP Oxymetazoline Related Compound A RS: Change N -(2-Aminoethyl)-2-[4-(tert-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide. $C_{16}H_{26}N_2O_2$ 278.39 to: N -(2-Aminoethyl)-2-[4-(tert-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide hydrochloride.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OXYMETAZOLINE HYDROCHLORIDE	IMPURITIES/Organic Impurities/Table 2	<i>First Supplement to USP39–NF34</i>	8116	30-Sep-2016		1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	$C_{16}H_{26}N_2O_2 \cdot HCl$ 314.85 Row 2 of Column 1: Change Oxymetazoline related compound A to: Oxymetazoline related compound A ^a AND Add footnote a: <i>N</i> -(2-Aminoethyl)-2-[4-(<i>tert</i> -butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide. Line 9: Delete (2 <i>S</i> ,3 <i>aS</i> ,7 <i>aS</i>)-1-[(<i>S</i>)-2-[(<i>R</i>)-1-Ethoxy-1-oxopentan-2-ylamino]propanoyl]octahydro-1 <i>H</i> -indole-2-carboxylic acid
PERINDOPRIL ERBUMINE	CHEMICAL INFORMATION	<i>First Supplement to USP39–NF34</i>	8127	30-Sep-2016		1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 9: Delete (2 <i>S</i> ,3 <i>aS</i> ,7 <i>aS</i>)-1-[(<i>S</i>)-2-[(<i>R</i>)-1-Ethoxy-1-oxopentan-2-ylamino]propanoyl]octahydro-1 <i>H</i> -indole-2-carboxylic acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PERINDOPRIL ERBUMINE	ADDITIONAL R EQUIREMENT S/USP Reference Standards <11>	<i>First Supplement to USP39–NF34</i>	8127	30-Sep-2016		1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 2 of USP Perindopril Related Compound A RS: Change (2S,3aS,7aS)-Octahydro-1H-indole-2-carboxylic acid hydrochloride. C ₁₇ H ₂₈ N ₂ O ₅ · HCl 205.68 to: (2S,3aS,7aS)-Octahydro-1H-indole-2-carboxylic acid. C ₉ H ₁₅ NO ₂ 169.22
PERINDOPRIL ERBUMINE	IM PUR ITIES/Organic Impurities/Table 2	<i>First Supplement to USP39–NF34</i>	8127	30-Sep-2016		1-Oct-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 2 of footnote g: Change octahydro to: octahydro

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DESLORATADINE	ADDITIONAL REQUIREMENTS	<i>Second Supplement to USP Reference Standards <11></i>	8607	30-Sep-2016		1-Oct-2016	<i>USP41–NF36</i>	<i>First Supplement to USP40–NF35</i>	Line 2 of USP Desloratadine Related Compound B RS: Change 8-Chloro-11-(1, 2,3,6-tetrahydro pyridin-4-yl)-6,1 1-di hydro-5 <i>H</i> -benzo[5,6]cyclohepta[1,2- <i>b</i>]pyridine. C ₁₉ H ₁₉ ClN ₂ 310.82 to: 8-Chloro-11-(1, 2,3,6-tetrahydro pyridin-4-yl)-6,1 1-di hydro-5 <i>H</i> -benzo[5,6]cyclohepta[1,2- <i>b</i>]pyridine hydrochloride. C ₁₉ H ₂₀ Cl ₂ N ₂ 347.28
EXTRACTABLES	REFERENCES	<i>USP39–NF34</i>	1835	29-Jul-2016		1-Aug-2016	<i>USP41–NF36</i>	<i>First Supplement to</i>	Delete references 5, 7,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ASSOCIATED WITH PHARMA CEUTICAL PACKAGING SYSTEMS								USP40–NF35	9, and 12.
ASSESSMENT REFERENCES OF DRUG PRODUCT LEACHABLES ASSOCIATED WITH PHARMA CEUTICAL PACKAGING/DELIVERY SYSTEMS	REFERENCES	USP39–NF34	1850	29-Jul-2016		1-Aug-2016	USP41–NF36	First Supplement to USP40–NF35	Delete reference 8.
ORALLY INHALED AND NASAL DRUG PRODUCTS	REFERENCES	USP39–NF34	1862	29-Jul-2016		1-Aug-2016	USP41–NF36	First Supplement to USP40–NF35	Delete reference 3.
FELBAMATE ORAL SUSPENSION	PERFORMANCE TESTS/ Dissolution <711>	USP39–NF34	3855	29-Jul-2016		1-Aug-2016	USP41–NF36	First Supplement to USP40–NF35	Line 4 of System suitability: Change [Note—The relative retention times for methylparaben and felbamate are about 0.5 and 1.0,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
									respectively.] to: [Note—The relative retention times for felbamate and methylparaben are about 1.0 and 1.5, respectively.]
FEXOFENADINE HYDROCHLORIDE	CHEMICAL INFORMATION	USP39–NF34	3895	29-Jul-2016		1-Aug-2016	USP41–NF36	First Supplement to USP40–NF35	Line 7: Change [138452-21-8]. to: [153439-40-8].
FLUORESCEIN SODIUM	IMPURITIES/Organic Impurities	USP39–NF34	3960	29-Jul-2016		1-Aug-2016	USP41–NF36	First Supplement to USP40–NF35	Row 7 of column 1 of Table 2: Change Total impurities to: Total unspecified impurities
GRANISETRON HYDROCHLORIDE	USP Reference standards <11>	USP39–NF34	4151	29-Jul-2016		1-Aug-2016	USP41–NF36	First Supplement to USP40–NF35	Line 2 of USP Granisetron Related Compound B RS: Change (N-[(1R,3r,5)-9-Methyl-9-a

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GRANISETRO	USP Reference USP39–NF34	4153	29-Jul-2016	1-Aug-2016	USP41–NF36	First	zabicyclo[3.3.1]non-3-yl]-1<i>H</i>-indazole-3-carboxamide). to: (<i>N</i>-[(1<i>R</i>,3<i>r</i>,5<i>S</i>)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1<i>H</i>-indazole-3-carboxamide). AND Line 2 of USP Granisetron Related Compound E RS: Change ((1<i>R</i>,3<i>r</i><i>S</i>,5<i>S</i>)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine, acetate salt). to: ((1<i>R</i>,3<i>r</i>,5<i>S</i>)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine, acetate salt). Line 2 of USP

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
N HYDROCHL standards <11> ORIDE INJECTION						<i>Supplement to USP40–NF35</i>	Granisetron Related Compound B RS: Change (N-[(1R,3r,5)-9-Methyl-9-a zabicyclo[3.3.1] non-3-yl]-1H -indazole-3-carb oxamide). to: N-[(1R,3r,5S)-9-Methyl-9-az abicyclo[3.3.1]n on-3-y l]-1H -indazole-3-carb oxamide.
GRANISETRO USP Reference N HYDROCHL standards <11> ORIDE TABLETS	USP39–NF34	4155	29-Jul-2016	1-Aug-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 2 of USP Granisetron Related Compound B RS: Change (N-[(1R,3r,5)-9-Methyl-9-a zabicyclo[3.3.1] non-3-yl]-1H -indazole-3-carb oxamide).

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
									to: N-[(1 <i>R</i> ,3 <i>r</i> ,5 <i>S</i>)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1 <i>H</i> -indazole-3-carboxamide.
HALCINONIDE CREAM	IMPURITIES/ <i>Organic Impurities/Chromatographic system</i>	USP39–NF34	4176	29-Jul-2016		1-Aug-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 1 of <i>Column</i> : Change 1.8-μm packing L1 to: 1.7-μm packing L1
HALOPERIDOL DECANOATE	IMPURITIES/ <i>Organic Impurities/Table 2</i>	USP39–NF34	4184	29-Jul-2016		1-Aug-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Footnote k: Change 4-(4?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. to: 4-(3?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
KETOROLAC T ADDITIONAL R ROMETHAMIN EQUIREMENT E INJECTION S/USP Reference Standards <11>	USP39–NF34	4468	29-Jul-2016	1-Aug-2016	USP41–NF36	First Supplement to USP40–NF35	AND Footnote I: Change 4-(3?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. to: 4-(4?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. Line 4 of USP Ketorolac Related Compound A RS: Change 358.15 to: 358.39 AND Line 3 of USP Ketorolac Related Compound B RS: Change 227.09

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LOVASTATIN	USP Reference standards <11>	USP39–NF34	4631	29-Jul-2016		1-Aug-2016	USP41–NF36	First Supplement to USP40–NF35	to: 227.26 AND Line 3 of USP Ketorolac Related Compound C RS: Change 225.09 to: 225.24 AND Line 3 of USP Ketorolac Related Compound D: Change 211.1 to: 211.3 Line 2 of USP Lovastatin Related Compound A RS: Change [Dihydro-lovastatin][butanoic acid, 2-methyl-, 1,2,3,4,4a,7,8,8a-octahydro-3,7-dimethyl-8-[2(t

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NAPROXEN	ASSAY/	USP39–NF34 4993	29-Jul-2016	1-Aug-2016	USP41–NF36	First	etrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1?(R*), 3?, 7?, 8?(2S*, 4S*), -8??]]]-. to: (1S, 3S, 4aR, 7S, 8S, 8aS)-8-{2-[(2R, 4R)-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl (S)-2-methylbutanoate. Line 1 of <i>Tailing</i>

Monograph Title Section		Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	<i>Procedure/System suitability/Suitability requirements</i>						<i>Supplement to USP40–NF35</i>	<i>factor: Change NLT 2.0 to: NMT 2.0</i>
NAPROXEN TABLETS	IM PURITIES/ <i>Organic Impurities</i>	USP39–NF34	4993	29-Jul-2016	1-Aug-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 6 of <i>Analysis</i> : Change Result = $(r_U/r_S) \times (C_U/C_S) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$
RIZATRIPTAN BENZOATE TABLETS	PERFORMANCE TESTS/ <i>Dissolution <711>/Chromatographic procedure</i>	USP39–NF34	5750	29-Jul-2016	1-Aug-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Add Buffer: 1.36 g/L of monobasic potassium phosphate. Adjust the pH of the solution with phosphoric acid to 2.5.
SIMETHICONE	ASSAY/ <i>Procedure/Analysis</i>	USP39–NF34	5843	29-Jul-2016	1-Aug-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	Line 1 of <i>Samples</i> : Change <i>Standard stock solution, Standard solution, Sample stock solution, and</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SIMVASTATIN IM TABLETS	PUR ITIES/ <i>Organic Impurities/Analysis</i>	USP39–NF34	5848	29-Jul-2016		1-Aug-2016	USP41–NF36	<i>First Supplement to USP40–NF35</i>	<i>Sample solution to:</i> <i>Standard solution and Sample solution</i> Line 5: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ AND Delete the variable definitions for M_{r1} and M_{r2}.

Pagination

- [First page « First](#)
- [Previous page < Previous](#)
- ...
- [Page 21](#)
- [Page 22](#)
- [Page 23](#)
- [Page 24](#)
- [Page 25](#)
- [Page 26](#)
- [Page 27](#)
- [Page 28](#)

-
- [Page 29](#)
 - ...
 - [Next page Next ›](#)
 - [Last page Last »](#)